

## **PBS criteria for Evolocumab (PCSK9i): Familial homozygous hypercholesterolaemia**

Evolocumab is a human monoclonal antibody that binds to proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibiting PCSK9 in the circulation from binding to the LDL receptor on the liver cell surface. This inhibition prevents PCSK9-mediated LDL receptor degradation resulting in reduced serum LDL cholesterol.

PBS authority is required for the prescription of Evolocumab. The criteria are as follows:

### **Familial homozygous hypercholesterolaemia (in conjunction with dietary therapy and exercise)**

Initial treatment (must be treated by a specialist physician)

- The condition must be confirmed by genetic testing OR a Dutch Lipid Clinic Network Score of at least 7  
**AND**
- the patient must have an LDL cholesterol level > 2.6 mmol/L  
**AND**
- Patient must have been treated with the maximum recommended dose of atorvastatin (80 mg daily) or rosuvastatin (40 mg daily) or maximum tolerated dose for at least 12 consecutive weeks UNLESS unable to take this due to adverse event or contraindication

For more detailed information:

<https://www.pbs.gov.au/medicine/item/10958R>